TouchIMMUNOLOGY got the opportunity to catch up with Prof. Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss the final recommendations from the DORIS taskforce in defining remission in systemic lupus erythematosus.
The abstract ‘The 2021 DORIS Definition Of Remission In SLE – Final Recommendations from an International Task Force.‘ (OP0296), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- Why has there been a lack of consensus over the definition of remission in systemic lupus erythematosus (SLE)? (0:14)
- What have been the limitations of the potential definitions of remission? (1:07)
- Could you tell us a little about the DORIS Taskforce, its members and objectives? (3:01)
Disclosures: Ronald Van Vollenhoven discloses receiving research support (institutional grants): BMS, GSK, Lilly, UCB; support for educational programs (institutional grants): Pfizer, Roche; consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Servier, UCB; speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer UCB.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
